메뉴 건너뛰기




Volumn 102, Issue 26-27, 2005, Pages 1984-1985

Central venous catheter and malignant diseases: The value of thrombosis prophylaxis is questioned;Central venkateter och malign sjukdom: Värdet av trombosprofylax ifrågasätts nu

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; HEPARIN; WARFARIN;

EID: 21644434439     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey
Times cited : (3)

References (6)
  • 2
    • 1842556758 scopus 로고    scopus 로고
    • Thrombotic complications of central venous catheters in cancer patients
    • Kuter DJ. Thrombotic complications of central venous catheters in cancer patients [review]. Oncologist 2004;9(2):207-16.
    • (2004) Oncologist , vol.9 , Issue.2 , pp. 207-216
    • Kuter, D.J.1
  • 3
    • 0035864991 scopus 로고    scopus 로고
    • Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2
    • Eastman ME, Khorsand M, Maki DG, Williams EC, Kim K, Sondel PM, et al. Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2. Cancer 2001;91(4):806-14.
    • (2001) Cancer , vol.91 , Issue.4 , pp. 806-814
    • Eastman, M.E.1    Khorsand, M.2    Maki, D.G.3    Williams, E.C.4    Kim, K.5    Sondel, P.M.6
  • 4
    • 0036379760 scopus 로고    scopus 로고
    • Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis
    • Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J 2002;32(3):84-8.
    • (2002) Intern Med J , vol.32 , Issue.3 , pp. 84-88
    • Heaton, D.C.1    Han, D.Y.2    Inder, A.3
  • 5
    • 1842517901 scopus 로고    scopus 로고
    • A phase III randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weight heparin (dalteparin sodium, fragmin) in preventing catheter-related complications (CRCs) in cancer patients with central venous catheters (CVCs)
    • Reichardt P, Kretzschmar A, Biakhov M, Irwin D, Slabber C, Miller L, et al. A phase III randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weight heparin (dalteparin sodium, fragmin) in preventing catheter-related complications (CRCs) in cancer patients with central venous catheters (CVCs). Proc Am Soc Clin Oncol 2002;21:369a.
    • (2002) Proc Am Soc Clin Oncol , vol.21
    • Reichardt, P.1    Kretzschmar, A.2    Biakhov, M.3    Irwin, D.4    Slabber, C.5    Miller, L.6
  • 6
    • 4644288189 scopus 로고    scopus 로고
    • Prevention of venous thromboembolism: The Seventh ACCP Conference on Anti-thrombotic andThrombolytic Therapy
    • Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Anti-thrombotic andThrombolytic Therapy. Chest 2004;126(3 Suppl):338S-400S.
    • (2004) Chest , vol.126 , Issue.3 SUPPL.
    • Geerts, W.H.1    Pineo, G.F.2    Heit, J.A.3    Bergqvist, D.4    Lassen, M.R.5    Colwell, C.W.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.